Ann: Clinical Trial Update, page-2

Respiri limited (ASX: RSH) (“Respiri” or the “Company”) is pleased to report the first clinical study to demonstrate the clinical relevance of the company’s digital wheeze detection technology is in progress with wheezoTM performing to expectations.The aim of this first study is to compare and correlate wheezo’s acoustic respiratory monitoring technology and wheeze rate as a measurement of wheeze severity in patients with clinician assessment of wheeze severity, including chest auscultation using a stethoscope. It is the first of two short studies designed to provide further evidence for the company’s healthcare professional (HCP) education program and to provide the evidence required to achieve endorsement by asthma bodies such as Asthma Australia, Asthma UK and the respiratory community.As announced on 29 April 2019, when ethics approval was received, Professor Francis Thien, Director of Respiratory Medicine at Eastern Health is the Principal Investigator recruiting patients upon admission to Box Hill Hospital with an exacerbation of asthma or COPD, causing wheeze. Recruitment is ongoing, and we have amended the protocol to include emergency patients to increase the numbers of subjects with severe disease and take the opportunity to test the technology in the ED setting. While we await approval for the amendment, we continue to record the wheeze rate of every patient who is admitted to the hospital presenting with wheeze upon admission and again, upon discharge.Whilst Respiri will not be providing a preliminary analysis of the data prior to publication of the abstract, we are pleased to report the effectiveness of the noise cancellation feature implemented in the new product design with the addition of the second microphone for background noise. wheezoTM and its technology upgrade to better detect and measure wheeze rate is working without fail in the challenging hospital environment